<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EJNMMI Res</journal-id><journal-id journal-id-type="iso-abbrev">EJNMMI Res</journal-id><journal-title-group><journal-title>EJNMMI Research</journal-title></journal-title-group><issn pub-type="epub">2191-219X</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39729173</article-id><article-id pub-id-type="pmc">PMC11680535</article-id>
<article-id pub-id-type="publisher-id">1189</article-id><article-id pub-id-type="doi">10.1186/s13550-024-01189-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Discrimination of benign, atypical, and malignant peripheral nerve sheath tumours in neurofibromatosis type 1 &#x02013; intraindividual comparison of positron emission computed tomography and diffusion-weighted magnetic resonance imaging</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3032-2321</contrib-id><name><surname>Ristow</surname><given-names>Inka</given-names></name><address><email>i.ristow@uke.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0290-7186</contrib-id><name><surname>Apostolova</surname><given-names>Ivayla</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8454-8863</contrib-id><name><surname>Kaul</surname><given-names>Michael G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1463-0885</contrib-id><name><surname>Stark</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8467-0508</contrib-id><name><surname>Zapf</surname><given-names>Antonia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4991-8544</contrib-id><name><surname>Schmalhofer</surname><given-names>Marie-Lena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mautner</surname><given-names>Victor F.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3596-5932</contrib-id><name><surname>Farschtschi</surname><given-names>Said</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7976-3868</contrib-id><name><surname>Adam</surname><given-names>Gerhard</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7102-534X</contrib-id><name><surname>Bannas</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salamon</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2491-1346</contrib-id><name><surname>Well</surname><given-names>Lennart</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Department of Diagnostic and Interventional Radiology and Nuclear Medicine, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Martinistra&#x000df;e 52, 20246 Hamburg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Institute of Medical Biometry and Epidemiology, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Department of Neurology, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff4"><label>4</label>Department of Diagnostic and Interventional Radiology, Medical Care Center Beste Trave, Bad Oldesloe, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>127</elocation-id><history><date date-type="received"><day>2</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To intraindividually compare the diagnostic performance of positron emission computed tomography (F-18-FDG-PET/CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) in a non-inferiority design for the discrimination of peripheral nerve sheath tumours as benign (BPNST), atypical (ANF), or malignant (MPNST) in patients with neurofibromatosis type 1 (NF1).</p></sec><sec><title>Results</title><p id="Par2">In this prospective single-centre study, thirty-four NF1 patients (18 male; 30&#x02009;&#x000b1;&#x02009;11 years) underwent F-18-FDG-PET/CT and multi-b-value DW-MRI (11 b-values 0&#x000a0;&#x02013;&#x000a0;800&#x000a0;s/mm&#x000b2;) at 3T. Sixty-six lesions corresponding to 39 BPNST, 11 ANF, and 16 MPNST were evaluated. Two radiologists independently assessed the maximum standardized uptake value (SUV<sub>max</sub>) and mean and minimum apparent diffusion coefficient (ADC<sub>mean/min</sub>) as well as the ADC in areas of lowest signal intensity in each lesion (ADC<sub>dark</sub>). The AUCs of DW-MRI and F-18-FDG-PET/CT were compared to determine whether the ADC is non-inferior to SUV<sub>max</sub> (non-inferiority margin equal to -10%). Follow-up of &#x02265;&#x02009;24 months (BPNST) or histopathological evaluation (MPNST&#x02009;+&#x02009;ANF) served as diagnostic reference standard. Both SUV<sub>max</sub> and ADC parameters demonstrated good diagnostic accuracy (AUC<sub>SUVmax</sub> 94.0%; AUC<sub>ADCmean/min/dark</sub> 91.6% / 90.1% / 92.5%). However, non-inferiority could not be demonstrated for any of the three ADC parameters (lower limits of the confidence intervals of the difference between the AUC of ADC<sub>mean/min/dark</sub> and SUV<sub>max</sub> -12.9% / -14.5% / -11.6%). Inter-rater reliability was excellent for both imaging techniques (Krippendorff&#x02019;s alpha all &#x0003e;&#x02009;0.94).</p></sec><sec><title>Conclusions</title><p id="Par3">Both PET/CT-derived SUV<sub>max</sub> and MRI-derived ADC allow sensitive and non-invasive differentiation of benign and (pre)-malignant peripheral nerve sheath tumours. Nevertheless, DW-MRI cannot be considered as non-inferior to F-18-FDG-PET/CT in this prospective single-centre study.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13550-024-01189-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ADC</kwd><kwd>Atypical neurofibroma</kwd><kwd>DWI</kwd><kwd>MPNST</kwd><kwd>MRI</kwd><kwd>NF1</kwd><kwd>Nerve sheath tumour</kwd><kwd>PET</kwd><kwd>SUV</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;tsklinikum Hamburg-Eppendorf (UKE) (5411)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Neurofibromatosis type 1 (NF1) is an autosomal-dominant neurogenetic disorder with an incidence of about 1:2500&#x02013;1:3000 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. NF1 is caused by a pathogenic variant in the <italic>NF1</italic>-gene on 17q11.2 affecting the tumour-suppressing protein neurofibromin [<xref ref-type="bibr" rid="CR3">3</xref>]. Patients with NF1 present with a characteristic phenotype including caf&#x000e9;-au-lait spots, Lisch nodules, skinfold freckling, spinal deformities as well as central and peripheral nerve sheath tumours, with the latter being neurofibromas [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par5">Benign peripheral nerve sheath tumours (BPNST), especially internal plexiform neurofibromas originating from the large peripheral nerves, can grow to large size and cause pain and motor dysfunction [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] contributing to reduced quality of life in affected patients [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Plexiform neurofibromas require monitoring due to their inherent risk of malignant transformation into highly aggressive sarcomas (MPNST). Early detection of such malignant transformation is critical for individual patient outcome. Malignant transformation of benign tumours is observed in 8&#x000a0;&#x02013;&#x000a0;16% of NF1 patients and is the most contributing factor to NF1-related death [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par6">Neurofibromas with cytological atypia or hypercellularity are considered atypical neurofibromas (ANF). Furthermore, the term atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) is pathologically defined by the presence of at least two of the following criteria: nuclear atypia, hypercellularity, variable loss of neurofibroma architecture, and/or mitotic activity beyond isolated mitotic figures (&#x0003e;&#x02009;1/50 high-power field and &#x0003c;&#x02009;3/10 high-power field) [<xref ref-type="bibr" rid="CR11">11</xref>]. The terms ANF and ANNUBP are not identical but have been used interchangeably, leading to potential confusion. However, both ANF and ANNUBP are considered pre-malignant tumours with distinct epigenetic profiling different from BPNST and MPNST [<xref ref-type="bibr" rid="CR12">12</xref>] which are not prone to metastasis or recurrence after complete resection [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par8">Magnetic resonance imaging (MRI) with diffusion-weighted imaging is the gold standard imaging technique for long-term monitoring of NF1-associated tumours due to its excellent soft tissue contrast [<xref ref-type="bibr" rid="CR14">14</xref>]. Further advantages of MRI are that a contrast agent does not necessarily have to be administered and that the patient is not exposed to ionizing radiation. According to current tumour surveillance guidelines for NF1 patients, whole-body MRI should be performed at least at the transition from childhood to adulthood to assess internal tumour burden, which has been correlated with the risk of developing an MPNST [<xref ref-type="bibr" rid="CR15">15</xref>]. Follow-up scans should therefore be planned under consideration of the respective internal tumour load.</p><p id="Par9">Beyond the evaluation of morphological tumour characteristics, including volumetric assessment of internal tumour burden, the use of diffusion-weighted MRI (DW-MRI) as a functional and quantitative imaging technique has been proven useful in detecting transformation into atypical and/or malignant stages [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par10">18-F-fluorodeoxyglucose positron emission imaging is recommended in case of suspected malignant transformation [<xref ref-type="bibr" rid="CR15">15</xref>] but is associated with radiation exposure.</p><p id="Par11">Most of the previous studies investigating the diagnostic performance of DW-MRI and/or PET imaging for the discrimination of NF1-associated peripheral nerve sheath tumours are limited to the comparison of benign vs. malignant tumours, hereby neglecting ANF/ANNUBP in their study design [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. In a meta-analysis, the maximum standardized uptake value (SUV<sub>max</sub>) demonstrated high diagnostic accuracy for the discrimination of benign and malignant peripheral nerve sheath tumours. Highest sensitivity of 0.99 was achieved with an SUV<sub>max</sub> cut-off value of &#x02265;&#x02009;3.5 with a specificity of 0.75 [<xref ref-type="bibr" rid="CR32">32</xref>]. Regarding DW-MRI, in particular, the mean and minimum apparent diffusion coefficient (ADC<sub>mean/min</sub>), as well as the ADC in the slice with the lowest signal intensity (ADC<sub>dark</sub>) were proposed as quantitative imaging parameters, demonstrating good performance for the discrimination of benign vs. malignant when using an ADC<sub>min</sub> cut-off value of &#x02264;&#x02009;1&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and &#x02264;&#x02009;1.54&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s for ADC<sub>dark</sub> [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par12">Few studies included atypical tumours in their evaluations by showing that pre-malignant ANF cluster in between the benign and malignant tumours with respect to metabolic activity in 18-FDG-PET imaging as well as diffusion restriction in DW-MRI. For example, Fertitta et al. reported a mean SUV<sub>max</sub> of 8.3&#x02009;&#x000b1;&#x02009;4.7 for MPNSTs, while SUV<sub>max</sub> was 5.3&#x02009;&#x000b1;&#x02009;0.6 in neurofibromas with atypia, and 5.6&#x02009;&#x000b1;&#x02009;1.3 in ANNUBP [<xref ref-type="bibr" rid="CR33">33</xref>]. The observations were consistent with those of Warbey et al. in which the SUV<sub>max</sub> of atypical neurofibromas clustered between those of benign neurofibromas and MPNST [<xref ref-type="bibr" rid="CR34">34</xref>]. Adding to this, Ristow et al. provided evidence for an intermediate diffusion restriction profile in ANFs between that of benign and malignant peripheral nerve sheath tumours [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par13">However, it should be taken into account that the use of different machines, imaging protocols, image reconstruction techniques, and post-processing software causes variability in F-18-FDG-PET/CT or DW-MRI measurements [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. Therefore, it is not possible to define appropriate diagnostic cut-off values that can be applied with the same degree of reliability in different facilities.</p><p id="Par14">At present, it is not sufficiently clear to what extent diffusion-weighted imaging can be regarded as an equivalent method to discriminate NF1-associated tumours with suspected malignant transformation in routine clinical practice. Data on intraindividual comparison of PET/CT and DW-MRI are missing. Therefore, the purpose of this study was to intraindividually compare the diagnostic performance of positron emission computed tomography (F-18-FDG-PET/CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) for the discrimination of peripheral nerve sheath tumours in patients with neurofibromatosis type 1 (NF1) as benign, atypical, or malignant.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par15">This prospective single-centre study was approved by the local ethics committee (&#x000c4;rztekammer Hamburg; PV4691). Written informed consent to publish was obtained from all patients. All procedures complied with the local data protection guidelines.</p><sec id="Sec3"><title>Study population</title><p id="Par16">Inclusion criteria were a confirmed NF1 diagnosis by genetic testing and availability of diffusion-weighted magnetic resonance imaging (DW-MRI) at 3T with multiple b-values as well as F-18-FDG-PET/CT. DW-MRI and matching F-18-FDG-PET/CT had to be no more than six weeks apart. Consecutive recruitment was performed from 08/2014 to 12/2021. Data on the reasons for the imaging, especially the patients&#x02019; clinical symptoms such as pain, were not systematically collected. Following the STARD recommendations for reporting diagnostic studies, a flow chart illustrating the participants&#x02019; flow through the study is attached to Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>. Histopathological evaluation after surgical resection served as the diagnostic reference standard for MPNST and ANF. Resected MPNST were classified according to the grading system of the F&#x000e9;d&#x000e9;ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par17">As performed previously, tumours were considered benign when no changes in size or appearance were present in follow-up examinations within 24 months [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec4"><title>Imaging</title><sec id="Sec5"><title>DW-MRI data acquisition</title><p id="Par18">MR imaging was performed at 3T (Philips Ingenia, Best, The Netherlands). The detailed scanning protocol was reported previously [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par19">In short, local DWI stacks were scanned covering each tumour of interest. The DW-MRI protocol used an axial respiratory-triggered spin-echo planar imaging (EPI) sequence (parallel acquisition; sense factor 2.8; TR 2300 ms; TE 67 ms; echo train length 43; flip angle 90&#x000b0;; slice thickness 3&#x000a0;mm; intersection gap 0&#x000a0;mm; matrix 124&#x02009;&#x000d7;&#x02009;122; FOV 270&#x02009;&#x000d7;&#x02009;270&#x000a0;mm; voxel size 1.5&#x02009;&#x000d7;&#x02009;1.5&#x02009;&#x000d7;&#x02009;3&#x000a0;mm; SPAIR; two averages) with eleven b-values (0, 10, 20, 30, 50, 70, 100, 300, 400, 600, 800&#x000a0;s/mm<sup>2</sup>). Scan time of the DW-MRI was about 6&#x000a0;&#x02013;&#x000a0;7&#x000a0;min.</p></sec><sec id="Sec6"><title>F-18-FDG-PET/CT data acquisition and image reconstruction</title><p id="Par20">The PET imaging protocol required a fasting period of at least 6&#x000a0;h and a blood glucose level of &#x02264;&#x02009;200&#x000a0;mg/dl before F-18-FDG administration. The average F-18-FDG injection dose was 287&#x02009;&#x000b1;&#x02009;56 MBq (range 147&#x000a0;&#x02013;&#x000a0;397 MBq). During the uptake period of 79&#x02009;&#x000b1;&#x02009;18&#x000a0;min (range 44&#x000a0;&#x02013;&#x000a0;114&#x000a0;min), patients were hydrated orally with water.</p><p id="Par21">From 08/2014 to 11/2018 F-18-FDG-PET/CT imaging was performed using a Gemini GXL 10 scanner PET/CT (Philips Healthcare, Best, The Netherlands; n<sub>tumours</sub> = 37) and from 12/2018 to 12/2021 using a Vereos whole-body TOF-PET/CT (Philips Healthcare, Best, The Netherlands; n<sub>tumours</sub> = 29). The detailed imaging protocols for both scanners were reported previously [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par22">In brief, PET/CT acquisition was performed from skull vertex to toes in each patient.</p><p id="Par23">Philips Gemini GXL 10 attenuation correction was performed using auxiliary CT with 50 mAs, 120&#x000a0;kV, rotation time 0.5&#x000a0;s, spiral pitch factor 1.1 reconstructed with 5&#x000a0;mm slice thickness (512&#x02009;&#x000d7;&#x02009;512 matrix; 1.17&#x02009;&#x000d7;&#x02009;1.17&#x000a0;mm pixel size). PET images were acquired with 90&#x000a0;s per bed position for the trunk (60&#x000a0;s for the extremities) and reconstructed using iterative 3DLOR reconstruction algorithm with default parameter settings (e.g., two iterations; no subsets; voxel size 4.0&#x02009;&#x000d7;&#x02009;4.0&#x02009;&#x000d7;&#x02009;4.0&#x000a0;mm).</p><p id="Par24">PET images acquired with Vereos whole-body TOF-PET/CT were performed with 90&#x000a0;s per bed position for the trunk (60&#x000a0;s extremities) and reconstructed with auxiliary CT-based attenuation and scatter correction using the blob-ordered subset time-of-flight reconstruction algorithm of the system (2 iterations; 10 subsets; reconstructed voxel size 2.0&#x02009;&#x000d7;&#x02009;2.0&#x02009;&#x000d7;&#x02009;2.0&#x000a0;mm). The attenuation map was generated from the whole-body low-dose CT scan (50 mAs/120&#x000a0;kV; rotation time 0.5; spiral pitch factor 0.8) reconstructed with a slice thickness of 3&#x000a0;mm (matrix size 512&#x02009;&#x000d7;&#x02009;512; pixel size 1.17&#x02009;&#x000d7; 1.17&#x000a0;mm).</p></sec></sec><sec id="Sec7"><title>Data analysis</title><sec id="Sec8"><title>DW-MRI data analysis</title><p id="Par25">DW-MRI data were processed as described previously [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] using a self-developed image-analysis framework (qMapIt) [<xref ref-type="bibr" rid="CR42">42</xref>] extending the open-source software ImageJ [<xref ref-type="bibr" rid="CR43">43</xref>]. In brief, quantitative parametric maps were calculated by nonlinear regression with pixel-wise fitting of signal intensities over the spectrum of b-values to the corresponding model. A monoexponential function was applied for ADC determination in ImageJ. Regarding ADC measurements, regions of interest (ROIs) were independently placed by the two readers by manual contouring of the tumours in the diffusion images (b-value 50&#x000a0;s/mm<sup>2</sup>). ROIs were placed along tumour margins in three adjacent slices with the largest axial tumour diameter. Averaged values from the three ROIs were calculated to assess the mean and minimum apparent diffusion coefficient (ADC<sub>mean/min</sub>). Additionally, a single ROI was placed along tumour margins at the visually lowest signal intensity to determine ADC<sub>dark</sub>.</p></sec><sec id="Sec9"><title>F-18-FDG-PET/CT data analysis</title><p id="Par26">F-18-FDG-PET/CT data were analyzed using the software ROVER v3.0.61&#x000a0;h (ABX advanced biochemical compounds GmbH, Radeberg, Germany). Data analysis was performed independently by two readers (IR and LW) as described by others [<xref ref-type="bibr" rid="CR44">44</xref>]. In brief, 3d spheres covering the entire tumour volume were manually placed based on the attenuation-corrected emission data using the non-enhanced CT images for anatomical orientation. The metabolically active part of the peripheral nerve sheath tumour was delineated by an automatic algorithm based on adaptive thresholding. A detailed description of the algorithm has been published elsewhere [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. When necessary, a click-based manual correction of the ROI was performed to exclude metabolically active adjacent structures, e.g. the brain.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par27">This article is based on preliminary work aiming to define ADC-based diagnostic cut-off values to classify NF1-associated peripheral nerve sheath tumours as benign, atypical, or malignant [<xref ref-type="bibr" rid="CR22">22</xref>]. All patients from the former study with DW-MRI and a time-matched F-18-FDG-PET/CT were included in the cohort of the current study.</p><p id="Par28">Considering the preceding study, this article is based on secondary evaluations; the results are therefore presented descriptively. Statistical analysis was performed using the software R, version 4.1.3 [<xref ref-type="bibr" rid="CR47">47</xref>]. Mean and minimum ADC values from each of the three ROIs per lesion were averaged to ADC<sub>mean</sub> and ADC<sub>min</sub>. There were no missing values in the complete data set. ANF and ANNUBP were considered together as the ANF group. To compare each ADC and SUV<sub>max</sub> value between the three tumour groups (BPNST, ANF and MPNST), a linear mixed model was calculated [<xref ref-type="bibr" rid="CR48">48</xref>] with an ADC or SUV<sub>max</sub> value as one of the dependent variables, respectively. The tumour group and reader were included as fixed effects and a random-intercept was included for each patient. Estimated marginal means and their pairwise contrasts with two-sided 95% confidence intervals (95%-CI) were calculated. Krippendorff&#x02019;s alpha with bootstrapped 95%-CI was assessed to quantify interrater agreement [<xref ref-type="bibr" rid="CR49">49</xref>]. A non-parametric multi-factorial approach was applied to calculate the area-under-the-curve (AUC) of the ADC values and the SUV<sub>max</sub> value [<xref ref-type="bibr" rid="CR50">50</xref>]. For this purpose and according to Ristow et al. (2024) [<xref ref-type="bibr" rid="CR22">22</xref>], the three-level reference standard was dichotomized in two ways of discrimination:</p><p id="Par29">
<list list-type="bullet"><list-item><p id="Par30">Discrimination 1: BPNST vs. ANF&#x02009;+&#x02009;MPNST.</p></list-item><list-item><p id="Par31">Discrimination 2: BPNST&#x02009;+&#x02009;ANF vs. MPNST.</p></list-item></list>
</p><p id="Par32">Considering the clinical implications, the resulting AUC curves of this article are based on Discrimination 1 as the primary comparison, as both suspected ANF or MPNST require further diagnostic workup such as additional F-18-FDG-PET/CT and/or invasive approaches such as biopsy or surgical resection.</p><p id="Par33">To evaluate whether ADC values are non-inferior compared to the SUV<sub>max</sub>, the difference between the ADC value and SUV<sub>max</sub> with two-sided 95%-CI were calculated, respectively [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. After careful consideration, taking into account the specific cohort and clinical question, and aiming to balance realistic discriminatory power and tolerance, the non-inferiority margin was set to -10%, which is within the range of commonly applied non-inferiority margin sizes [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par34">To report correlations between the ADC values and SUV<sub>max</sub>, geometric means of two multilevel model coefficients were calculated with two-sided 95%-CI, respectively. The multilevel models contain SUV<sub>max</sub> and the ADC value as the dependent variable and fixed effect and vice versa. Furthermore, they include the reader as fixed effect and a random intercept per patient.</p></sec></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Study population and reference standard</title><p id="Par35">Thirty-four NF1 patients (18 male; mean age 30&#x02009;&#x000b1;&#x02009;11 years, range 12&#x000a0;&#x02013;&#x000a0;54 years) were identified, corresponding to 39 BPNST, 11 ANF, and 16 MPNST. Fifteen patients had more than one lesion. Among these, two patients had two ANF. No patient had multiple MPNST. There was no BPNST that underwent subsequent transition into an MPNST. All ANF were excised, therefore none transformed into an MPNST.</p><p id="Par36">Histopathological reports following MPNST resection revealed 1 grade I, 6 grade II, and 9 grade III tumours according to F&#x000e9;d&#x000e9;ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).</p></sec><sec id="Sec13"><title>Distribution of ADC parameters and SUVmax of BPNSTs, ANFs, and MPNSTs</title><p id="Par37">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows exemplary axial T2w images and ADC maps of a BPNST, ANF, and MPNST in the thigh of three different patients, including the respective ROI placement and the corresponding F-18-FDG-PET/CT. Estimated marginal means and 95%-CI for the three evaluated DW-MRI-derived ADC parameters and F-18-FDG-PET/CT-derived SUV<sub>max</sub> are given in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>A and are visualized in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Results of mixed models used to estimate the marginal means for comparing ADC values between tumour groups are given in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>.</p><p id="Par38">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Comparison of T2-weighted SPAIR MRI, parametric ADC maps, and F-18-FDG-PET/CT in three different NF1 patients with nerve sheath tumours of the thigh. Left column: BPNST (arrowhead) in a 54-year-old female; middle column: ANF (arrowhead) in a 49-year-old female, right column: MPNST (arrowhead) in a 31-year-old male. First row: transverse slices of a T2-weighted SPAIR sequence at 3T (* depict the femoral bone); second row: ROI contouring along the tumour margins in diffusion images (b-value 50&#x000a0;s/mm<sup>2</sup>); third row: corresponding parametric ADC maps; fourth row: fused F-18-FDG-PET/CT; fifth row: F-18-FDG-PET. BPNST&#x02009;=&#x02009;benign peripheral nerve sheath tumour; ANF&#x02009;=&#x02009;atypical neurofibroma; MPNST&#x02009;=&#x02009;malignant peripheral nerve sheath tumour; SUV&#x02009;=&#x02009;standardized uptake value</p></caption><graphic xlink:href="13550_2024_1189_Fig1_HTML" id="d33e629"/></fig>
</p><p id="Par39">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Estimated marginal means for ADC<sub>mean</sub>, ADC<sub>min</sub>, ADC<sub>dark</sub>, and SUV<sub>max</sub> of benign, atypical, and malignant peripheral nerve sheath tumours. ADC<sub>mean</sub> = mean apparent diffusion coefficient; ADC<sub>min</sub> = minimum apparent diffusion coefficient; ADC<sub>dark</sub> = apparent diffusion coefficient in the slice with lowest signal intensity; BPNST&#x02009;=&#x02009;benign peripheral nerve sheath tumour; ANF&#x02009;=&#x02009;atypical neurofibroma; MPNST&#x02009;=&#x02009;malignant peripheral nerve sheath tumour; CI&#x02009;=&#x02009;confidence interval</p></caption><graphic xlink:href="13550_2024_1189_Fig2_HTML" id="d33e655"/></fig>
</p><p id="Par40">Differences of the ADC values and p-values of the pairwise comparisons are displayed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>B. All pairwise comparisons of BPNST vs. ANF vs. MPNST group revealed p-values&#x02009;&#x0003c;&#x02009;0.01.</p></sec><sec id="Sec14"><title>ROC-AUC analysis for BPNST, ANF, and MPNST discrimination</title><p id="Par41">Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> visualizes the ROC curves of Discrimination 1 (BPNST vs. ANF&#x02009;+&#x02009;MPNST) for the three ADC parameters and SUV<sub>max</sub>. Corresponding AUC values including 95%-CI for the four parameters are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> for Discrimination 1 and 2, respectively. Regarding Discrimination 1, the AUC was 91.6% (95%-CI: 79.6&#x000a0;&#x02013;&#x000a0;96.9) for ADC<sub>mean</sub>, 90.1% (95%-CI: 78.8&#x000a0;&#x02013;&#x000a0;95.7) for ADC<sub>min</sub>, 92.5% (81.3&#x000a0;&#x02013;&#x000a0;97.2) for ADC<sub>dark</sub>, and 94.0% (84.1&#x000a0;&#x02013;&#x000a0;97.9) for SUV<sub>max</sub>. Potential ADC-based diagnostic cut-off values for BPNST, ANF, and MPNST discrimination have already been reported in previous work [<xref ref-type="bibr" rid="CR21">21</xref>]. Potential SUV<sub>max</sub>-based diagnostic cut-off values for BPNST, ANF, and MPNST discrimination are provided in Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>.</p><p id="Par42">
<fig id="Fig3"><label>Fig. 3</label><caption><p>ROC AUC curves visualizing diagnostic performance for the primary comparison BPNST vs. ANF&#x02009;+&#x02009;MPNST (Discrimination 1). Top left: mean apparent diffusion coefficient (ADC<sub>mean</sub>); top right: minimum apparent diffusion coefficient (ADC<sub>min</sub>); mean apparent diffusion coefficient (ADC<sub>mean</sub>); bottom left: apparent diffusion coefficient in the slice with the lowest signal intensity (ADC<sub>dark</sub>); bottom right: maximum standardized uptake value (SUV<sub>max</sub>). Both DW-MRI and F-18-FDG-PET/CT reveal good diagnostic performance to discriminate BPNST from ANF or MPNST with mean AUCs&#x02009;&#x0003e;&#x02009;90%</p></caption><graphic xlink:href="13550_2024_1189_Fig3_HTML" id="d33e710"/></fig>
</p><p id="Par43">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Estimated marginal means and pairwise comparisons of ADC<sub>mean</sub>, ADC<sub>min</sub>, ADC<sub>dark</sub>, and SUV<sub>max</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">A) Estimated marginal means</th><th align="left" colspan="2">ADC parameter</th><th align="left">BPNST<break/>(<italic>n</italic>&#x02009;=&#x02009;78*)</th><th align="left">ANF<break/>(<italic>n</italic>&#x02009;=&#x02009;22*)</th><th align="left" colspan="2">MPNST<break/>(<italic>n</italic>&#x02009;=&#x02009;32*)</th></tr></thead><tbody><tr><td align="left" rowspan="4"/><td align="left" colspan="2">ADC<sub>mean</sub> [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">2.13 (2.02&#x000a0;&#x02013;&#x000a0;2.23)</td><td align="left">1.66 (1.51&#x000a0;&#x02013;&#x000a0;1.81)</td><td align="left" colspan="2">1.37 (1.24&#x000a0;&#x02013;&#x000a0;1.49)</td></tr><tr><td align="left" colspan="2">ADC<sub>min</sub> [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">1.59 (1.47&#x000a0;&#x02013;&#x000a0;1.71)</td><td align="left">1.08 (0.91&#x000a0;&#x02013;&#x000a0;1.26)</td><td align="left" colspan="2">0.78 (0.63&#x000a0;&#x02013;&#x000a0;0.92)</td></tr><tr><td align="left" colspan="2">ADC<sub>dark</sub> [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">2.08 (1.96&#x000a0;&#x02013;&#x000a0;2.19)</td><td align="left">1.58 (1.42&#x000a0;&#x02013;&#x000a0;1.74)</td><td align="left" colspan="2">1.28 (1.15&#x000a0;&#x02013;&#x000a0;1.42)</td></tr><tr><td align="left" colspan="2">SUV<sub>max</sub> (95%-CI)</td><td align="left">3.58 (2.28&#x000a0;&#x02013;&#x000a0;4.89)</td><td align="left">6.22 (4.40&#x000a0;&#x02013;&#x000a0;8.04)</td><td align="left" colspan="2">11.48 (9.96&#x000a0;&#x02013;&#x000a0;13.01)</td></tr><tr><td align="left">
<bold>B) Pairwise comparisons</bold>
</td><td align="left" colspan="2">
<bold>ADC parameter</bold>
</td><td align="left">
<bold>BPNST vs. ANF</bold>
</td><td align="left">
<bold>BPNST vs. MPNST</bold>
</td><td align="left" colspan="2">
<bold>ANF vs. MPNST</bold>
</td></tr><tr><td align="left" rowspan="8"/><td align="left" rowspan="2">ADC<sub>mean</sub></td><td align="left">Difference [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">0.47 (0.30&#x000a0;&#x02013;&#x000a0;0.63)</td><td align="left">0.76 (0.63&#x000a0;&#x02013;&#x000a0;0.89)</td><td align="left" colspan="2">0.30 (0.12&#x000a0;&#x02013;&#x000a0;0.47)</td></tr><tr><td align="left">p-value</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left" colspan="2">0.0011</td></tr><tr><td align="left" rowspan="2">ADC<sub>min</sub></td><td align="left">Difference [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">0.51 (0.31&#x000a0;&#x02013;&#x000a0;0.70)</td><td align="left">0.82 (0.66&#x000a0;&#x02013;&#x000a0;0.97)</td><td align="left" colspan="2">0.31 (0.10&#x000a0;&#x02013;&#x000a0;0.52)</td></tr><tr><td align="left">p-value</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left" colspan="2">0.0046</td></tr><tr><td align="left" rowspan="2">ADC<sub>dark</sub></td><td align="left">Difference [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">0.50 (0.32&#x000a0;&#x02013;&#x000a0;0.67)</td><td align="left">0.79 (0.65&#x000a0;&#x02013;&#x000a0;0.93)</td><td align="left" colspan="2">0.30 (0.11&#x000a0;&#x02013;&#x000a0;0.49)</td></tr><tr><td align="left">p-value</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left">&#x0003c;&#x02009;0.0001</td><td align="left" colspan="2">0.0027</td></tr><tr><td align="left" rowspan="2">SUV<sub>max</sub></td><td align="left">Difference [&#x000d7; 10<sup>&#x02212;&#x02009;3</sup> mm<sup>2</sup>/s] (95%-CI)</td><td align="left">-2.64 (-4.60 &#x02013; -0.67)</td><td align="left" colspan="2">-7.90 (-9.43 &#x02013; -6.38)</td><td align="left">-5.27 (-7.37 &#x02013; -3.16)</td></tr><tr><td align="left">p-value</td><td align="left">0.0091</td><td align="left" colspan="2">&#x0003c;&#x02009;0.0001</td><td align="left">&#x0003c;&#x02009;0.0001</td></tr></tbody></table><table-wrap-foot><p>ADC<sub>mean</sub> = mean apparent diffusion coefficient; ADC<sub>min</sub> = minimum apparent diffusion coefficient; ADC<sub>dark</sub> = apparent diffusion coefficient in the slice with lowest signal intensity; BPNST&#x02009;=&#x02009;benign peripheral nerve sheath tumour; ANF&#x02009;=&#x02009;atypical neurofibroma; MPNST&#x02009;=&#x02009;malignant peripheral nerve sheath tumour; CI&#x02009;=&#x02009;confidence interval. * N was assessed by multiplication of the number of tumours (39 BPNSTs, 11 ANFs, 16 MPNSTs) by the number of readers (<italic>n</italic>&#x02009;=&#x02009;2)</p></table-wrap-foot></table-wrap>
</p><p id="Par44">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>ROC-analysis-derived AUC for DW-MRI-based ADC parameters and F-18-FDG-PET/CT-based SUV<sub>max</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Comparison</th><th align="left">AUC ADC<sub>mean</sub> [%] (95%-CI)</th><th align="left">AUC ADC<sub>min</sub> [%] (95%-CI)</th><th align="left">AUC ADC<sub>dark</sub> [%] (95%-CI)</th><th align="left">AUC SUV<sub>max</sub> [%] (95%-CI)</th></tr></thead><tbody><tr><td align="left">BPNST vs. ANF&#x02009;+&#x02009;MPNST</td><td align="left"><p>91.6</p><p>(79.6&#x000a0;&#x02013;&#x000a0;96.9)</p></td><td align="left"><p>90.1</p><p>(78.8&#x000a0;&#x02013;&#x000a0;95.7)</p></td><td align="left"><p>92.5</p><p>(81.3&#x000a0;&#x02013;&#x000a0;97.2)</p></td><td align="left"><p>94.0</p><p>(84.1&#x000a0;&#x02013;&#x000a0;97.9)</p></td></tr><tr><td align="left">BPNST&#x02009;+&#x02009;ANF vs. MPNST</td><td align="left"><p>95.8</p><p>(87.7&#x000a0;&#x02013;&#x000a0;98.7)</p></td><td align="left"><p>93.3</p><p>(86.3&#x000a0;&#x02013;&#x000a0;96.9)</p></td><td align="left"><p>94.4</p><p>(86.1&#x000a0;&#x02013;&#x000a0;97.9)</p></td><td align="left"><p>91.5</p><p>(73.9&#x000a0;&#x02013;&#x000a0;97.6)</p></td></tr></tbody></table><table-wrap-foot><p>ADC<sub>mean</sub> = mean apparent diffusion coefficient; ADC<sub>min</sub> = minimum apparent diffusion coefficient; ADC<sub>dark</sub> = apparent diffusion coefficient in the slice with lowest signal intensity; SUVmax&#x02009;=&#x02009;maximum standardized uptake value; BPNST&#x02009;=&#x02009;benign peripheral nerve sheath tumour; ANF&#x02009;=&#x02009;atypical neurofibroma; MPNST&#x02009;=&#x02009;malignant peripheral nerve sheath tumour; CI&#x02009;=&#x02009;confidence interval</p></table-wrap-foot></table-wrap>
</p><p id="Par45">Best SUV<sub>max</sub>-based BPNST vs. ANF&#x02009;+&#x02009;MPNST discrimination was obtained using a cut-off value of 5 resulting in a sensitivity of 85.2% (62.7&#x000a0;&#x02013;&#x000a0;95.2) and specificity of 92.3% (77.4&#x000a0;&#x02013;&#x000a0;97.7).</p></sec><sec id="Sec15"><title>Inter-rater reliability (Krippendorff&#x02019;s alpha)</title><p id="Par46">The agreement between the two readers was excellent for all investigated parameters. Krippendorff&#x02019;s alpha for ADC<sub>mean</sub> was 0.98 (95%-CI: 0.95&#x02013;0.99). For ADC<sub>min</sub>, Krippendorff&#x02019;s alpha was 0.94 (0.85&#x000a0;&#x02013;&#x000a0;0.98), for ADC<sub>dark</sub> 0.97 (0.93&#x000a0;&#x02013;&#x000a0;0.99), and for SUV<sub>max</sub> it was &#x0003e;&#x02009;0.99 (0.92&#x000a0;&#x02013;&#x000a0;1.00).</p></sec><sec id="Sec16"><title>Test for non-inferiority of DW-MRI compared to F-18-FDG-PET/CT</title><p id="Par47">A non-inferiority plot of the three DW-MRI-derived parameters compared to SUV<sub>max</sub> for Discrimination 1 (BPNST vs. ANF&#x02009;+&#x02009;MPNST) is visualized in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. The difference between the AUC of ADC<sub>mean</sub> and SUV<sub>max</sub> was -2.4% (-12.9% &#x02013; 8.17%). Regarding ADC<sub>min</sub> and SUV<sub>max</sub>, the difference between the AUCs was -3.9% (-14.5% &#x02013; 6.6%), and for ADC<sub>dark</sub> the difference was -1.6% (-11.6% &#x02013; 8.5%). Non-inferiority could hence not be demonstrated for any of the three ADC parameters, as the lower limits of the confidence intervals (-12.9% / -14.5% / -11.6%) were below the a priori-defined non-inferiority margin of -10%.</p><p id="Par48">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Non-inferiority plot of the three DW-MRI-derived parameters for the primary comparison BPNST vs. ANF&#x02009;+&#x02009;MPNST. In all three evaluated DW-MRI-based parameters, the lower confidence interval of the differences of the AUCs of the ADC and SUV<sub>max</sub> was below the a priori-defined non-inferiority limit of -10%. Consequently, non-inferiority could not be demonstrated</p></caption><graphic xlink:href="13550_2024_1189_Fig4_HTML" id="d33e1105"/></fig>
</p></sec><sec id="Sec17"><title>Correlation between ADC and SUVmax</title><p id="Par49">There was a negative correlation between the three ADC parameters and SUV<sub>max</sub> for comparison 1 (BPNST vs. ANF&#x02009;+&#x02009;MPNST). Correlation coefficients revealed moderate negative association for ADC<sub>mean</sub> (<italic>r</italic> = -0.60 (95%-CI: -0.74 &#x02013; -0.46)), ADC<sub>min</sub> (<italic>r</italic> = -0.58 (95%-CI: -0.72 &#x02013; -0.44)), and ADC<sub>dark</sub> (<italic>r</italic> = -0.58 (95%-CI: -0.72 &#x02013; -0.44)) with SUV<sub>max</sub>, respectively (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par50">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Correlation plots of SUV<sub>max</sub> and the three DW-MRI-derived ADC parameters for the primary comparison BPNST vs. ANF&#x02009;+&#x02009;MPNST. Correlation coefficients revealed moderate negative association for ADC<sub>mean</sub> (<italic>r</italic> = -0.60), ADC<sub>min</sub> (<italic>r</italic> = -0.58), and ADC<sub>dark</sub> (<italic>r</italic> = -0.58) with SUV<sub>max</sub></p></caption><graphic xlink:href="13550_2024_1189_Fig5_HTML" id="d33e1162"/></fig>
</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par51">In this study, we intraindividually compared the diagnostic accuracy of F-18-FDG-PET/CT and DW-MRI for the discrimination of NF1-associated peripheral nerve sheath tumours as benign, atypical, or malignant. A non-inferiority study design with a margin of -10% was conducted to compare the AUC of F-18-FDG-PET/CT-derived maximum standardized uptake value (SUV<sub>max</sub>) with the AUC of DW-MRI-derived mean and minimum apparent diffusion coefficient (ADC<sub>mean/min</sub>) as well as the ADC in the slice with the lowest signal intensity (ADC<sub>dark</sub>). Both imaging techniques demonstrated utility with good overall diagnostic accuracy (AUC<sub>SUVmax</sub> 94.0%; AUC<sub>ADCmean/min/dark</sub> 91.6% / 90.1% / 92.5%) and excellent inter-rater reliability (Krippendorff&#x02019;s alpha all &#x02265;&#x02009;0.94).</p><p id="Par52">However, non-inferiority could not be demonstrated for any of the three ADC parameters (lower limits of the confidence intervals of the difference between the AUC of AUC<sub>ADCmean/min/dark</sub> and SUV<sub>max</sub> -12.9% / -14.5% / -11.6%). We therefore conclude that despite the advantages of ionization radiation-free DW-MRI, PET imaging should still be considered the diagnostic gold standard in the case of suspected malignant transformation in peripheral nerve sheath tumours. Nevertheless, MRI remains an important mainstay in the diagnosis of NF1-associated peripheral nerve sheath tumours, particularly given its better suitability for screening purposes. In contrast, the collective is pre-selected in PET/CT, as there is already a suspicion of MPNST.</p><p id="Par53">In line with previous work and according to their histopathological classification as pre-malignant tumours, the SUV<sub>max</sub> as well as the ADC of the ANF clustered between the BPNST and MPNST [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par54">It should be noted that the more complex statistical approach now involving three tumour groups (BPNST, ANF, and MPNST) instead of only two in most of the previous literature (BPNST vs. MPNST) is reflected by a lower discriminatory power. For example, a meta-analysis by Martin et al. reported pooled diagnostic accuracies for differentiating between BPNST and MPNST were higher for SUV<sub>max</sub>, with the best accuracy being achieved with a cut-off value of 3.5 (sensitivity 0.99, specificity 0.75) [<xref ref-type="bibr" rid="CR32">32</xref>]. In accordance, the best accuracy was achieved in our data for the BPNST vs. ANF&#x02009;+&#x02009;MPNST comparison with a comparable cut-off value of 4.0 (sensitivity 0.93, specificity 0.72; Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par55">It should be taken into account that besides the SUV<sub>max</sub>, which is quickly measurable and certainly considered the most widely used semi-quantitative parameter across centres in routine clinical practice, there are also other PET-derived parameters in the literature, which have been evaluated for the differentiation of peripheral nerve sheath tumours in NF1, e.g., the mean SUV, heterogeneity index, or tumour-to-liver, -muscle, and -fat ratio [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref>]. We have refrained from including these parameters in the current analysis, as they play a rather secondary role in the current standard of care.</p><p id="Par56">The negative correlation between the F-18-FDG-PET/CT-derived SUV<sub>max</sub> and the DW-MRI-derived ADC values in our study was comparable to that reported by others for other tumour entities [<xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. As both high SUV<sub>max</sub> and low ADC values are associated with tumour malignancy, the identified correlation appears reasonable.</p><p id="Par57">In addition to the use of histomorphological features only, CDKN2A/B mutation analysis is now routinely performed for diagnosing malignant transformation in peripheral nerve sheath tumours. Homozygous loss of this cell cycle regulator is considered an additional marker for the conversion of benign into pre-malignant or malignant peripheral nerve sheath tumours [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. A review of the records revealed a homozygous loss in only five ANF in our collective, a heterozygous loss in one lesion, and no mutation in the CDKN2A/B gene in 3 ANF. According to the patient chart, the remaining tumours did not undergo any further genetic analyses. Beyond that, other markers - like methylation profiling - seem to strengthen the validity of histopathological analysis [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par58">The study has the following limitations: First, the relatively small number of MPNST and ANF as well as the long data acquisition period including two different PET/CT scanners, both of which are explicable by the rarity of the disease. However, this resulted in acquisition of PET images with inherently different spatial resolution, which impacts quantitative assessments including SUV<sub>max</sub> estimates. Nevertheless, we did not stratify the analysis according to the PET scanners due to the limited sample size. This might have caused a bias to the disadvantage of F-18-FDG-PET/CT resulting in underestimation of its discriminative power. Similarly and despite excellent interrater reliability, the ADC-based cut-off values obtained in our study should not be used at other institutions without previous correlation with institution specific ADC values due to intersystem and intervendor variability of ADC measurements [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par59">Second, given the long acquisition period, it should be taken into account that a WHO revision was carried out in 2021 including improved consensus criteria for the histomorphological diagnosis of ANF (referred to in the WHO as ANF or ANNUBP) [<xref ref-type="bibr" rid="CR61">61</xref>]. As a result, a corresponding variability in tumour classification of ANF vs. ANNUBP cannot be fully ruled out. However, none of the included ANF/ANNUBP was retrospectively assigned the diagnosis MPNST, and ANF and ANNUBP were considered together in the statistical analysis.</p><p id="Par60">Third, the two techniques (DW-)MRI and PET imaging were considered as two separate imaging techniques in this study. Considering the increasing availability of PET/MRI, which allows to correlate information about local tumour metabolism with excellent morphological tumour visualization within one session, future studies must show whether synergistic effects can be achieved to increase diagnostic accuracy to discriminate between benign, atypical, and malignant peripheral nerve sheath tumours.</p></sec><sec id="Sec19"><title>Conclusion</title><p id="Par61">In conclusion, both F-18-FDG-PET/CT-derived SUV<sub>max</sub> and DW-MRI-derived ADC allow sensitive and non-invasive differentiation of benign and (pre)-malignant peripheral nerve sheath tumours in need of further diagnostic workup, e.g., by biopsy. Nevertheless, diffusion-weighted MRI cannot be considered an equivalent method to F-18-FDG-PET/CT in this single-centre study, and more imaging surrogates are desperately needed to provide a sufficient risk stratification for the decision-making process before biopsy and/or surgery.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13550_2024_1189_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Study conception: IR, LW, JS; planning of imaging sequences: JS, LW; DW-MRI data acquisition: IR, LW, JS, MK, M-LS; 18-F-FDG PET/CT data acquisition: IA; data and statistical analysis: IR, LW, MK, MS, AZ; manuscript drafting: IR, LW; contribution in writing &#x00026; revising the manuscript: IA, MK, MS, M-LS, AZ, VM, SF, GA, PB, JS. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>LW and JS were supported by a research grant from the &#x0201c;Werner-Otto-Stiftung&#x0201d; (grant no. 13/97). Further funding was provided to IR and JS by the German lay organization &#x0201c;Bundesverband Neurofibromatose e.V.&#x0201d; (grant no. n/a). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethical approval</title><p id="Par64">The study was approved by the local ethics committee (&#x000c4;rztekammer Hamburg, PV4691). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.</p></notes><notes id="FPar4"><title>Consent to participate</title><p id="Par65">Written informed consent to participate was obtained from all patients or, if participants were under 16, from a parent and/or legal guardian.</p></notes><notes id="FPar1"><title>Consent for publication</title><p id="Par62">Written informed consent was obtained from the patients for publication of this study and accompanying images.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">The authors report no conflict of interest. SF, JS, and LW have received speaker honoraria from Astra Zeneca and Alexion and compensation for advice or lecturing from Alexion not related to this study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lammert</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Kluwe</surname><given-names>L</given-names></name><name><surname>Mautner</surname><given-names>VF</given-names></name></person-group><article-title>Prevalence of neurofibromatosis 1 in German children at Elementary School Enrollment</article-title><source>Arch Dermatol</source><year>2005</year><pub-id pub-id-type="doi">10.1001/archderm.141.1.71</pub-id><pub-id pub-id-type="pmid">15655144</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at Elementary School Enrollment. Arch Dermatol. 2005. 10.1001/archderm.141.1.71.<pub-id pub-id-type="pmid">15655144</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Huson</surname><given-names>SM</given-names></name><name><surname>Compston</surname><given-names>DA</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name></person-group><article-title>A genetic study of Von Recklinghausen neurofibromatosis in South East Wales. II. Guidelines for genetic counselling</article-title><source>J Med Genet</source><year>1989</year><pub-id pub-id-type="doi">10.1136/jmg.26.11.712</pub-id><pub-id pub-id-type="pmid">2511319</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Huson SM, Compston DA, Harper PS. A genetic study of Von Recklinghausen neurofibromatosis in South East Wales. II. Guidelines for genetic counselling. J Med Genet. 1989. 10.1136/jmg.26.11.712.<pub-id pub-id-type="pmid">2511319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Fountain</surname><given-names>JW</given-names></name><name><surname>Wallace</surname><given-names>MR</given-names></name><name><surname>Bruce</surname><given-names>MA</given-names></name><name><surname>Seizinger</surname><given-names>BR</given-names></name><name><surname>Menon</surname><given-names>AG</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Physical mapping of a translocation breakpoint in neurofibromatosis</article-title><source>Science</source><year>1989</year><pub-id pub-id-type="doi">10.1126/science.2543076</pub-id><pub-id pub-id-type="pmid">2543076</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Fountain JW, Wallace MR, Bruce MA, Seizinger BR, Menon AG, Gusella JF, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science. 1989. 10.1126/science.2543076.<pub-id pub-id-type="pmid">2543076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Legius</surname><given-names>E</given-names></name><name><surname>Messiaen</surname><given-names>L</given-names></name><name><surname>Wolkenstein</surname><given-names>P</given-names></name><name><surname>Pancza</surname><given-names>P</given-names></name><name><surname>Avery</surname><given-names>RA</given-names></name><name><surname>Berman</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation</article-title><source>Genet Sci</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41436-021-01170-5</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Sci. 2021. 10.1038/s41436-021-01170-5.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>R</given-names></name><name><surname>Kluwe</surname><given-names>L</given-names></name><name><surname>Fuensterer</surname><given-names>C</given-names></name><name><surname>Kentsch</surname><given-names>M</given-names></name><name><surname>Friedrich</surname><given-names>RE</given-names></name><name><surname>Mautner</surname><given-names>VF</given-names></name></person-group><article-title>Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and Associated Clinical deficits</article-title><source>J Pediatr</source><year>2011</year><pub-id pub-id-type="doi">10.1016/j.jpeds.2011.04.008</pub-id><pub-id pub-id-type="pmid">21962598</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and Associated Clinical deficits. J Pediatr. 2011. 10.1016/j.jpeds.2011.04.008.<pub-id pub-id-type="pmid">21962598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>AM</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Akshintala</surname><given-names>S</given-names></name><name><surname>Baldwin</surname><given-names>A</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Ukwuani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1</article-title><source>Neuro Oncol</source><year>2018</year><pub-id pub-id-type="doi">10.1093/neuonc/noy067</pub-id><pub-id pub-id-type="pmid">29718344</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018. 10.1093/neuonc/noy067.<pub-id pub-id-type="pmid">29718344</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Merker</surname><given-names>VL</given-names></name><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Kassarjian</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>GJ</given-names></name><name><surname>Muzikansky</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis</article-title><source>Am J Med Genet A</source><year>2014</year><pub-id pub-id-type="doi">10.1002/ajmg.a.36466</pub-id><pub-id pub-id-type="pmid">24664633</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014. 10.1002/ajmg.a.36466.<pub-id pub-id-type="pmid">24664633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>HK</given-names></name><name><surname>Porteous</surname><given-names>A</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Haria</surname><given-names>K</given-names></name><name><surname>Griffiths</surname><given-names>A</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey</article-title><source>BMC Neurol</source><year>2023</year><pub-id pub-id-type="doi">10.1186/s12883-023-03429-7</pub-id><pub-id pub-id-type="pmid">37996843</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Yoo HK, Porteous A, Ng A, Haria K, Griffiths A, Lloyd A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023. 10.1186/s12883-023-03429-7.<pub-id pub-id-type="pmid">37996843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DGR</given-names></name><name><surname>Baser</surname><given-names>ME</given-names></name><name><surname>McGaughran</surname><given-names>J</given-names></name><name><surname>Sharif</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>E</given-names></name><name><surname>Moran</surname><given-names>A</given-names></name></person-group><article-title>Malignant peripheral nerve sheath tumours in neurofibromatosis</article-title><source>J Med Genet</source><year>2002</year><pub-id pub-id-type="doi">10.1136/jmg.39.5.311</pub-id><pub-id pub-id-type="pmid">12471212</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet. 2002. 10.1136/jmg.39.5.311.<pub-id pub-id-type="pmid">12471212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Uusitalo</surname><given-names>E</given-names></name><name><surname>Rantanen</surname><given-names>M</given-names></name><name><surname>Kallionp&#x000e4;&#x000e4;</surname><given-names>RA</given-names></name><name><surname>P&#x000f6;yh&#x000f6;nen</surname><given-names>M</given-names></name><name><surname>Lepp&#x000e4;virta</surname><given-names>J</given-names></name><name><surname>Yl&#x000e4;-Outinen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Distinctive cancer associations in patients with neurofibromatosis type 1</article-title><source>J Clin Oncol</source><year>2016</year><pub-id pub-id-type="doi">10.1200/JCO.2015.65.3576</pub-id><pub-id pub-id-type="pmid">26926675</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Uusitalo E, Rantanen M, Kallionp&#x000e4;&#x000e4; RA, P&#x000f6;yh&#x000f6;nen M, Lepp&#x000e4;virta J, Yl&#x000e4;-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016. 10.1200/JCO.2015.65.3576.<pub-id pub-id-type="pmid">26926675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>MM</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Quezado</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1&#x02014;a consensus overview</article-title><source>Hum Pathol</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.humpath.2017.05.010</pub-id><pub-id pub-id-type="pmid">28811252</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1&#x02014;a consensus overview. Hum Pathol. 2017. 10.1016/j.humpath.2017.05.010.<pub-id pub-id-type="pmid">28811252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Kresbach</surname><given-names>C</given-names></name><name><surname>Dottermusch</surname><given-names>M</given-names></name><name><surname>Eckhardt</surname><given-names>A</given-names></name><name><surname>Ristow</surname><given-names>I</given-names></name><name><surname>Paplomatas</surname><given-names>P</given-names></name><name><surname>Altendorf</surname><given-names>L</given-names></name><etal/></person-group><article-title>Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities</article-title><source>Neuro Oncol</source><year>2023</year><pub-id pub-id-type="doi">10.1093/neuonc/noad053</pub-id><pub-id pub-id-type="pmid">36866403</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kresbach C, Dottermusch M, Eckhardt A, Ristow I, Paplomatas P, Altendorf L, et al. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Neuro Oncol. 2023. 10.1093/neuonc/noad053.<pub-id pub-id-type="pmid">36866403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Beert</surname><given-names>E</given-names></name><name><surname>Brems</surname><given-names>H</given-names></name><name><surname>Dani&#x000eb;ls</surname><given-names>B</given-names></name><name><surname>Wever</surname><given-names>I</given-names></name><name><surname>De</surname><given-names>CF</given-names></name><name><surname>Van, Schoenaers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors</article-title><source>Genes Chromosomes Cancer</source><year>2011</year><pub-id pub-id-type="doi">10.1002/gcc.20921</pub-id><pub-id pub-id-type="pmid">21987445</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Beert E, Brems H, Dani&#x000eb;ls B, Wever I, De CF, Van, Schoenaers J, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011. 10.1002/gcc.20921.<pub-id pub-id-type="pmid">21987445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlawat</surname><given-names>S</given-names></name><name><surname>Blakeley</surname><given-names>JO</given-names></name><name><surname>Langmead</surname><given-names>S</given-names></name><name><surname>Belzberg</surname><given-names>AJ</given-names></name><name><surname>Fayad</surname><given-names>LM</given-names></name></person-group><article-title>Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis</article-title><source>Skeletal Radiol</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00256-019-03290-1</pub-id><pub-id pub-id-type="pmid">33094409</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skeletal Radiol. 2020. 10.1007/s00256-019-03290-1.<pub-id pub-id-type="pmid">33094409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Carton C, Gareth D, Blanco I, Friedrich RE, Ferner RE, Farschtschi S et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 on behalf of the ERN GENTURIS NF1 Tumour Management Guideline Group. 2023; 10.1016/j.eclinm.2022.101818</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Well</surname><given-names>L</given-names></name><name><surname>Salamon</surname><given-names>J</given-names></name><name><surname>Kaul</surname><given-names>MG</given-names></name><name><surname>Farschtschi</surname><given-names>S</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Geier</surname><given-names>KI</given-names></name><etal/></person-group><article-title>Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging</article-title><source>Neuro Oncol</source><year>2019</year><pub-id pub-id-type="doi">10.1093/neuonc/noy199</pub-id><pub-id pub-id-type="pmid">30496452</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Well L, Salamon J, Kaul MG, Farschtschi S, Herrmann J, Geier KI, et al. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro Oncol. 2019. 10.1093/neuonc/noy199.<pub-id pub-id-type="pmid">30496452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Demehri</surname><given-names>S</given-names></name><name><surname>Belzberg</surname><given-names>A</given-names></name><name><surname>Blakeley</surname><given-names>J</given-names></name><name><surname>Fayad</surname><given-names>LM</given-names></name></person-group><article-title>Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience</article-title><source>AJNR Am J Neuroradiol</source><year>2014</year><pub-id pub-id-type="doi">10.3174/ajnr.A3910</pub-id><pub-id pub-id-type="pmid">24763412</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol. 2014. 10.3174/ajnr.A3910.<pub-id pub-id-type="pmid">24763412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung Yun</surname><given-names>J</given-names></name><name><surname>Hee Lee</surname><given-names>M</given-names></name><name><surname>Min Lee</surname><given-names>S</given-names></name><name><surname>Seok Lee</surname><given-names>J</given-names></name><name><surname>Jung Kim</surname><given-names>H</given-names></name><name><surname>Joo Lee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI</article-title><source>Eur Radiol</source><year>2021</year><pub-id pub-id-type="doi">10.1007/s00330-020-07234-5</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Sung Yun J, Hee Lee M, Min Lee S, Seok Lee J, Jung Kim H, Joo Lee S, et al. Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI. Eur Radiol. 2021. 10.1007/s00330-020-07234-5.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>H</given-names></name><name><surname>Nishida</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Shimoyama</surname><given-names>Y</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Urakawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of Benign from malignant peripheral nerve sheath tumors</article-title><source>World Neurosurg</source><year>2022</year><volume>157</volume><fpage>e207</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2021.09.130</pub-id><pub-id pub-id-type="pmid">34624521</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Koike H, Nishida Y, Ito S, Shimoyama Y, Ikuta K, Urakawa H, et al. Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of Benign from malignant peripheral nerve sheath tumors. World Neurosurg. 2022;157:e207&#x02013;14. 10.1016/j.wneu.2021.09.130.<pub-id pub-id-type="pmid">34624521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlawat</surname><given-names>S</given-names></name><name><surname>Fayad</surname><given-names>LM</given-names></name></person-group><article-title>Imaging cellularity in benign and malignant peripheral nerve sheath tumors: utility of the target sign by diffusion weighted imaging</article-title><source>Eur J Radiol</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.ejrad.2018.03.018</pub-id><pub-id pub-id-type="pmid">30150045</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ahlawat S, Fayad LM. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: utility of the target sign by diffusion weighted imaging. Eur J Radiol. 2018. 10.1016/j.ejrad.2018.03.018.<pub-id pub-id-type="pmid">30150045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlawat</surname><given-names>S</given-names></name><name><surname>Blakeley</surname><given-names>JO</given-names></name><name><surname>Rodriguez</surname><given-names>FJ</given-names></name><name><surname>Fayad</surname><given-names>LM</given-names></name></person-group><article-title>Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1</article-title><source>Neurology</source><year>2019</year><pub-id pub-id-type="doi">10.1212/WNL.0000000000008092</pub-id><pub-id pub-id-type="pmid">31395668</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 2019. 10.1212/WNL.0000000000008092.<pub-id pub-id-type="pmid">31395668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Ristow</surname><given-names>I</given-names></name><name><surname>Kaul</surname><given-names>MG</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Zapf</surname><given-names>A</given-names></name><name><surname>Riedel</surname><given-names>C</given-names></name><name><surname>Lenz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI</article-title><source>Neurooncol Adv</source><year>2024</year><pub-id pub-id-type="doi">10.1093/noajnl/vdae021</pub-id><pub-id pub-id-type="pmid">38468867</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Ristow I, Kaul MG, Stark M, Zapf A, Riedel C, Lenz A, et al. Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI. Neurooncol Adv. 2024. 10.1093/noajnl/vdae021.<pub-id pub-id-type="pmid">38468867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Reinert</surname><given-names>CP</given-names></name><name><surname>Schuhmann</surname><given-names>MU</given-names></name><name><surname>Bender</surname><given-names>B</given-names></name><name><surname>Gugel</surname><given-names>I</given-names></name><name><surname>la Foug&#x000e8;re</surname><given-names>C</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2019</year><pub-id pub-id-type="doi">10.1007/s00259-018-4227-5</pub-id><pub-id pub-id-type="pmid">30535768</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Reinert CP, Schuhmann MU, Bender B, Gugel I, la Foug&#x000e8;re C, Sch&#x000e4;fer J, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019. 10.1007/s00259-018-4227-5.<pub-id pub-id-type="pmid">30535768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Salamon</surname><given-names>J</given-names></name><name><surname>Derlin</surname><given-names>T</given-names></name><name><surname>Bannas</surname><given-names>P</given-names></name><name><surname>Busch</surname><given-names>JD</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Bockhorn</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2013</year><pub-id pub-id-type="doi">10.1007/s00259-018-4227-5</pub-id><pub-id pub-id-type="pmid">23232507</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, et al. Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013. 10.1007/s00259-018-4227-5.<pub-id pub-id-type="pmid">23232507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Salamon</surname><given-names>J</given-names></name><name><surname>Veldhoen</surname><given-names>S</given-names></name><name><surname>Apostolova</surname><given-names>I</given-names></name><name><surname>Bannas</surname><given-names>P</given-names></name><name><surname>Yamamura</surname><given-names>J</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><etal/></person-group><article-title>18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: Tumour-to-liver ratio is superior to an SUVmax cut-off</article-title><source>Eur Radiol</source><year>2014</year><pub-id pub-id-type="doi">10.1007/s00330-013-3020-x</pub-id><pub-id pub-id-type="pmid">24097302</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, et al. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: Tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014. 10.1007/s00330-013-3020-x.<pub-id pub-id-type="pmid">24097302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Derlin</surname><given-names>T</given-names></name><name><surname>Tornquist</surname><given-names>K</given-names></name><name><surname>M&#x000fc;nster</surname><given-names>S</given-names></name><name><surname>Apostolova</surname><given-names>I</given-names></name><name><surname>Hagel</surname><given-names>C</given-names></name><name><surname>Friedrich</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1</article-title><source>Clin Nucl Med</source><year>2013</year><pub-id pub-id-type="doi">10.1097/RLU.0b013e318266ce84</pub-id><pub-id pub-id-type="pmid">23455531</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Derlin T, Tornquist K, M&#x000fc;nster S, Apostolova I, Hagel C, Friedrich RE, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013. 10.1097/RLU.0b013e318266ce84.<pub-id pub-id-type="pmid">23455531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Azizi</surname><given-names>AA</given-names></name><name><surname>Slavc</surname><given-names>I</given-names></name><name><surname>Theisen</surname><given-names>BE</given-names></name><name><surname>Rausch</surname><given-names>I</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Happak</surname><given-names>W</given-names></name><etal/></person-group><article-title>Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients?</article-title><source>Pediatr Blood Cancer</source><year>2018</year><pub-id pub-id-type="doi">10.1002/pbc.26733</pub-id><pub-id pub-id-type="pmid">28771999</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer. 2018. 10.1002/pbc.26733.<pub-id pub-id-type="pmid">28771999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Bredella</surname><given-names>MA</given-names></name><name><surname>Torriani</surname><given-names>M</given-names></name><name><surname>Hornicek</surname><given-names>F</given-names></name><name><surname>Ouellette</surname><given-names>HA</given-names></name><name><surname>Palmer</surname><given-names>WE</given-names></name><name><surname>Williams</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Value of PET in the assessment of patients with neurofibromatosis type I</article-title><source>Am J Roentgenol</source><year>2007</year><pub-id pub-id-type="doi">10.2214/AJR.07.2060</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, et al. Value of PET in the assessment of patients with neurofibromatosis type I. Am J Roentgenol. 2007. 10.2214/AJR.07.2060.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>W</given-names></name><name><surname>Friedrich</surname><given-names>RE</given-names></name><name><surname>Gawad</surname><given-names>KA</given-names></name><name><surname>Hagel</surname><given-names>C</given-names></name><name><surname>Von Deimling</surname><given-names>A</given-names></name><name><surname>De Wit</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2006</year><pub-id pub-id-type="doi">10.1007/s00259-005-0030-1</pub-id><pub-id pub-id-type="pmid">16832631</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Brenner W, Friedrich RE, Gawad KA, Hagel C, Von Deimling A, De Wit M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging. 2006. 10.1007/s00259-005-0030-1.<pub-id pub-id-type="pmid">16832631</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferner</surname><given-names>RE</given-names></name><name><surname>Golding</surname><given-names>JF</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Calonje</surname><given-names>E</given-names></name><name><surname>Jan</surname><given-names>W</given-names></name><name><surname>Sanjayanathan</surname><given-names>V</given-names></name><etal/></person-group><article-title>[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study</article-title><source>Ann Oncol</source><year>2008</year><pub-id pub-id-type="doi">10.1093/annonc/mdm450</pub-id><pub-id pub-id-type="pmid">17932395</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008. 10.1093/annonc/mdm450.<pub-id pub-id-type="pmid">17932395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferner</surname><given-names>RE</given-names></name><name><surname>Lucas</surname><given-names>JD</given-names></name><name><surname>O&#x02019;Doherty</surname><given-names>MJ</given-names></name><name><surname>Hughes</surname><given-names>RAC</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Cronin</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2000</year><pub-id pub-id-type="doi">10.1136/jnnp.68.3.353</pub-id><pub-id pub-id-type="pmid">10766898</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ferner RE, Lucas JD, O&#x02019;Doherty MJ, Hughes RAC, Smith MA, Cronin BF, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000. 10.1136/jnnp.68.3.353.<pub-id pub-id-type="pmid">10766898</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Geitenbeek</surname><given-names>RTJ</given-names></name><name><surname>Coert</surname><given-names>JH</given-names></name><name><surname>Hanff</surname><given-names>DF</given-names></name><name><surname>Graven</surname><given-names>LH</given-names></name><name><surname>Gr&#x000fc;nhagen</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis</article-title><source>Neuro Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.1093/neuonc/noaa280</pub-id><pub-id pub-id-type="pmid">33326583</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Martin E, Geitenbeek RTJ, Coert JH, Hanff DF, Graven LH, Gr&#x000fc;nhagen DJ, et al. A bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. Neuro Oncol. 2021. 10.1093/neuonc/noaa280.<pub-id pub-id-type="pmid">33326583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Fertitta</surname><given-names>L</given-names></name><name><surname>Jannic</surname><given-names>A</given-names></name><name><surname>Zehou</surname><given-names>O</given-names></name><name><surname>Bergqvist</surname><given-names>C</given-names></name><name><surname>Ferkal</surname><given-names>S</given-names></name><name><surname>Moryousef</surname><given-names>S</given-names></name><etal/></person-group><article-title>Whole-body Positron Emission Tomography with 18 F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the detection of Malignant Transformation in individuals with neurofibromatosis type 1</article-title><source>J Invest Dermatology</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jid.2024.01.028</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fertitta L, Jannic A, Zehou O, Bergqvist C, Ferkal S, Moryousef S, et al. Whole-body Positron Emission Tomography with 18 F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the detection of Malignant Transformation in individuals with neurofibromatosis type 1. J Invest Dermatology. 2024. 10.1016/j.jid.2024.01.028.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Warbey</surname><given-names>VS</given-names></name><name><surname>Ferner</surname><given-names>RE</given-names></name><name><surname>Dunn</surname><given-names>JT</given-names></name><name><surname>Calonje</surname><given-names>E</given-names></name><name><surname>O&#x02019;Doherty</surname><given-names>MJ</given-names></name></person-group><article-title>[18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2009</year><pub-id pub-id-type="doi">10.1007/s00259-008-1038-0</pub-id><pub-id pub-id-type="pmid">19142634</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Warbey VS, Ferner RE, Dunn JT, Calonje E, O&#x02019;Doherty MJ. [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009. 10.1007/s00259-008-1038-0.<pub-id pub-id-type="pmid">19142634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>OF</given-names></name><name><surname>Chong</surname><given-names>D</given-names></name><name><surname>Nanz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Diffusion-weighted MR imaging of upper abdominal organs: field strength and intervendor variability of apparent diffusion coefficients</article-title><source>Radiology</source><year>2014</year><pub-id pub-id-type="doi">10.1148/radiol.13130819</pub-id><pub-id pub-id-type="pmid">24475824</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Donati OF, Chong D, Nanz D, et al. Diffusion-weighted MR imaging of upper abdominal organs: field strength and intervendor variability of apparent diffusion coefficients. Radiology. 2014. 10.1148/radiol.13130819.<pub-id pub-id-type="pmid">24475824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Corona-Villalobos</surname><given-names>CP</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Halappa</surname><given-names>VG</given-names></name><etal/></person-group><article-title>Agreement and reproducibility of apparent diffusion coefficient measurements of dual-b-value and multi-b-value diffusion-weighted magnetic resonance imaging at 1.5 Tesla in phantom and in soft tissues of the abdomen</article-title><source>J Comput Assist Tomogr</source><year>2013</year><pub-id pub-id-type="doi">10.1097/RCT.0b013e3182720e07</pub-id><pub-id pub-id-type="pmid">23321832</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Corona-Villalobos CP, Pan L, Halappa VG, et al. Agreement and reproducibility of apparent diffusion coefficient measurements of dual-b-value and multi-b-value diffusion-weighted magnetic resonance imaging at 1.5 Tesla in phantom and in soft tissues of the abdomen. J Comput Assist Tomogr. 2013. 10.1097/RCT.0b013e3182720e07.<pub-id pub-id-type="pmid">23321832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Boellaard</surname><given-names>R</given-names></name></person-group><article-title>Standards for PET image acquisition and quantitative data analysis</article-title><source>J Nucl Med</source><year>2009</year><pub-id pub-id-type="doi">10.2967/jnumed.108.057182</pub-id><pub-id pub-id-type="pmid">19910429</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009. 10.2967/jnumed.108.057182.<pub-id pub-id-type="pmid">19910429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Trojani</surname><given-names>M</given-names></name><name><surname>Contesso</surname><given-names>G</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Rouesse</surname><given-names>J</given-names></name><name><surname>Bui</surname><given-names>NB</given-names></name><name><surname>de Mascarel</surname><given-names>A</given-names></name><name><surname>Goussot</surname><given-names>JF</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Bonichon</surname><given-names>F</given-names></name><name><surname>Lagarde</surname><given-names>C</given-names></name></person-group><article-title>Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system</article-title><source>Int J Cancer</source><year>1984</year><pub-id pub-id-type="doi">10.1002/ijc.2910330108</pub-id><pub-id pub-id-type="pmid">6693192</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984. 10.1002/ijc.2910330108.<pub-id pub-id-type="pmid">6693192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Ristow</surname><given-names>I</given-names></name><name><surname>Madesta</surname><given-names>F</given-names></name><name><surname>Well</surname><given-names>L</given-names></name><name><surname>Shenas</surname><given-names>FY</given-names></name><name><surname>Wright</surname><given-names>F</given-names></name><name><surname>Molwitz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evaluation of MRI-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1</article-title><source>Neuro Oncol</source><year>2022</year><pub-id pub-id-type="doi">10.1093/neuonc/noac100</pub-id><pub-id pub-id-type="pmid">35426432</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ristow I, Madesta F, Well L, Shenas FY, Wright F, Molwitz I, et al. Evaluation of MRI-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neuro Oncol. 2022. 10.1093/neuonc/noac100.<pub-id pub-id-type="pmid">35426432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Salamon</surname><given-names>J</given-names></name><name><surname>Papp</surname><given-names>L</given-names></name><name><surname>T&#x000f3;th</surname><given-names>Z</given-names></name><name><surname>Laqmani</surname><given-names>A</given-names></name><name><surname>Apostolova</surname><given-names>I</given-names></name><name><surname>Adam</surname><given-names>G</given-names></name><etal/></person-group><article-title>Nerve sheath tumors in neurofibromatosis type 1: Assessment of whole-body metabolic tumor burden using F-18-FDG PET/CT</article-title><source>PLoS ONE</source><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0143305</pub-id><pub-id pub-id-type="pmid">26625155</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Salamon J, Papp L, T&#x000f3;th Z, Laqmani A, Apostolova I, Adam G, et al. Nerve sheath tumors in neurofibromatosis type 1: Assessment of whole-body metabolic tumor burden using F-18-FDG PET/CT. PLoS ONE. 2015. 10.1371/journal.pone.0143305.<pub-id pub-id-type="pmid">26625155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zden</surname><given-names>C</given-names></name><name><surname>Mautner</surname><given-names>VF</given-names></name><name><surname>Farschtschi</surname><given-names>S</given-names></name><name><surname>Molwitz</surname><given-names>I</given-names></name><name><surname>Ristow</surname><given-names>I</given-names></name><name><surname>Bannas</surname><given-names>P</given-names></name><name><surname>Well</surname><given-names>L</given-names></name><name><surname>Klutmann</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>G</given-names></name><name><surname>Apostolova</surname><given-names>I</given-names></name><name><surname>Buchert</surname><given-names>R</given-names></name></person-group><article-title>Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden</article-title><source>J Neuroimaging</source><year>2024</year><pub-id pub-id-type="doi">10.1111/jon.13170</pub-id><pub-id pub-id-type="pmid">37942683</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">&#x000d6;zden C, Mautner VF, Farschtschi S, Molwitz I, Ristow I, Bannas P, Well L, Klutmann S, Adam G, Apostolova I, Buchert R. Asymmetry of thalamic hypometabolism on FDG-PET/CT in neurofibromatosis type 1: Association with peripheral tumor burden. J Neuroimaging. 2024. 10.1111/jon.13170.<pub-id pub-id-type="pmid">37942683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Ittrich</surname><given-names>H</given-names></name><name><surname>Kaul</surname><given-names>MG</given-names></name><name><surname>Groth</surname><given-names>M</given-names></name><name><surname>Tozakidou</surname><given-names>M</given-names></name><name><surname>Blohm</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional assessment of the kidneys in a 10 month-old child with renal artery stenosis by intravoxel incoherent motion</article-title><source>Nephrology</source><year>2017</year><pub-id pub-id-type="doi">10.1111/nep.12896</pub-id><pub-id pub-id-type="pmid">28205351</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Herrmann J, Ittrich H, Kaul MG, Groth M, Tozakidou M, Blohm M, et al. Functional assessment of the kidneys in a 10 month-old child with renal artery stenosis by intravoxel incoherent motion. Nephrology. 2017. 10.1111/nep.12896.<pub-id pub-id-type="pmid">28205351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nat Methods</source><year>2012</year><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012. 10.1038/nmeth.2089.<pub-id pub-id-type="pmid">22930834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Apostolova</surname><given-names>I</given-names></name><name><surname>Rogasch</surname><given-names>J</given-names></name><name><surname>Buchert</surname><given-names>R</given-names></name><name><surname>Wertzel</surname><given-names>H</given-names></name><name><surname>Achenbach</surname><given-names>HJ</given-names></name><name><surname>Schreiber</surname><given-names>J</given-names></name><etal/></person-group><article-title>Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC</article-title><source>BMC Cancer</source><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2407-14-896</pub-id><pub-id pub-id-type="pmid">25444154</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014. 10.1186/1471-2407-14-896.<pub-id pub-id-type="pmid">25444154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofheinz</surname><given-names>F</given-names></name><name><surname>P&#x000f6;tzsch</surname><given-names>C</given-names></name><name><surname>Oehme</surname><given-names>L</given-names></name><name><surname>Beuthien-Baumann</surname><given-names>B</given-names></name><name><surname>Steinbach</surname><given-names>J</given-names></name><name><surname>Kotzerke</surname><given-names>J</given-names></name><etal/></person-group><article-title>Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets</article-title><source>Nuklearmedizin</source><year>2012</year><pub-id pub-id-type="doi">10.3413/Nukmed-0419-11-07</pub-id><pub-id pub-id-type="pmid">22027997</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hofheinz F, P&#x000f6;tzsch C, Oehme L, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin. 2012. 10.3413/Nukmed-0419-11-07.<pub-id pub-id-type="pmid">22027997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofheinz</surname><given-names>F</given-names></name><name><surname>Langner</surname><given-names>J</given-names></name><name><surname>Petr</surname><given-names>J</given-names></name><name><surname>Beuthien-Baumann</surname><given-names>B</given-names></name><name><surname>Steinbach</surname><given-names>J</given-names></name><name><surname>Kotzerke</surname><given-names>J</given-names></name><etal/></person-group><article-title>An automatic method for accurate volume delineation of heterogeneous tumors in PET</article-title><source>Med Phys</source><year>2013</year><pub-id pub-id-type="doi">10.1118/1.4812892</pub-id><pub-id pub-id-type="pmid">24320478</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Hofheinz F, Langner J, Petr J, Beuthien-Baumann B, Steinbach J, Kotzerke J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys. 2013. 10.1118/1.4812892.<pub-id pub-id-type="pmid">24320478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022; URL: <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/.#">https://www.R-project.org/.#</ext-link></mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsova</surname><given-names>A</given-names></name><name><surname>Brockhoff</surname><given-names>PB</given-names></name><name><surname>Christensen</surname><given-names>RHB</given-names></name></person-group><article-title>lmerTest Package: tests in Linear mixed effects models</article-title><source>J Stat Softw</source><year>2017</year><pub-id pub-id-type="doi">10.18637/jss.v082.i13</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: tests in Linear mixed effects models. J Stat Softw. 2017. 10.18637/jss.v082.i13.</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">krippendorffsalpha. Measuring Agreement Using Krippendorff&#x02019;s Alpha Coefficient. R package version 1.1-1. <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=krippendorffsalpha">https://CRAN.R-project.org/package=krippendorffsalpha</ext-link></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Brunner E, Zapf A. Nonparametric ROC analysis for diagnostic trials. In: Balakrishnan N, editor. Methods and applications of statistics in clinical trials: planning, analysis, and inferential methods. John Wiley &#x00026; Sons, Inc; 2014;2. 10.1002/9781118596333.ch28.</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>ER</given-names></name><name><surname>DeLong</surname><given-names>DM</given-names></name><name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name></person-group><article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a Nonparametric Approach</article-title><source>Biometrics</source><year>1988</year><pub-id pub-id-type="doi">10.2307/2531595</pub-id><pub-id pub-id-type="pmid">3203132</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a Nonparametric Approach. Biometrics. 1988. 10.2307/2531595.<pub-id pub-id-type="pmid">3203132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Pong</surname><given-names>S</given-names></name><name><surname>Urner</surname><given-names>M</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>Mitsakakis</surname><given-names>N</given-names></name><name><surname>Seto</surname><given-names>W</given-names></name><name><surname>Hutchison</surname><given-names>JS</given-names></name><name><surname>Science</surname><given-names>M</given-names></name><name><surname>Daneman</surname><given-names>N</given-names></name></person-group><article-title>Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics</article-title><source>BMJ Open</source><year>2021</year><pub-id pub-id-type="doi">10.1136/bmjopen-2020-044480</pub-id><pub-id pub-id-type="pmid">33879485</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pong S, Urner M, Fowler RA, Mitsakakis N, Seto W, Hutchison JS, Science M, Daneman N. Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics. BMJ Open. 2021. 10.1136/bmjopen-2020-044480.<pub-id pub-id-type="pmid">33879485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Schwabe M, Spiridonov S, Yanik EL, Jennings JW, Hillen T, Ponisio M et al. How effective are Noninvasive tests for diagnosing malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1? Diagnosing MPNST in NF1 patients. 2019; 10.1155/2019/4627521</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>LL</given-names></name><name><surname>Drubach</surname><given-names>L</given-names></name><name><surname>Fahey</surname><given-names>F</given-names></name><name><surname>Irons</surname><given-names>M</given-names></name><name><surname>Voss</surname><given-names>S</given-names></name><name><surname>Ullrich</surname><given-names>NJ</given-names></name></person-group><article-title>[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation</article-title><source>J Neurooncol</source><year>2012</year><pub-id pub-id-type="doi">10.1007/s11060-012-0840-5</pub-id><pub-id pub-id-type="pmid">23238972</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Tsai LL, Drubach L, Fahey F, Irons M, Voss S, Ullrich NJ. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012. 10.1007/s11060-012-0840-5.<pub-id pub-id-type="pmid">23238972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Gucht</surname><given-names>A</given-names></name><name><surname>Zehou</surname><given-names>O</given-names></name><name><surname>Djelbani-Ahmed</surname><given-names>S</given-names></name><name><surname>Valeyrie-Allanore</surname><given-names>L</given-names></name><name><surname>Ortonne</surname><given-names>N</given-names></name><name><surname>Brugi&#x000e8;res</surname><given-names>P</given-names></name><etal/></person-group><article-title>Metabolic Tumour Burden measured by 18F-FDG PET/CT predicts Malignant Transformation in patients with neurofibromatosis Type-1</article-title><source>PLoS ONE</source><year>2016</year><pub-id pub-id-type="doi">10.1371/journal.pone.0151809</pub-id><pub-id pub-id-type="pmid">26987124</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">van der Gucht A, Zehou O, Djelbani-Ahmed S, Valeyrie-Allanore L, Ortonne N, Brugi&#x000e8;res P, et al. Metabolic Tumour Burden measured by 18F-FDG PET/CT predicts Malignant Transformation in patients with neurofibromatosis Type-1. PLoS ONE. 2016. 10.1371/journal.pone.0151809.<pub-id pub-id-type="pmid">26987124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CS</given-names></name><name><surname>Gong</surname><given-names>N</given-names></name><name><surname>Chu</surname><given-names>YC</given-names></name><name><surname>Anthony</surname><given-names>MP</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV</article-title><source>Eur J Radiol</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ejrad.2011.09.003</pub-id><pub-id pub-id-type="pmid">22386916</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wong CS, Gong N, Chu YC, Anthony MP, Chan Q, Lee HF, et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol. 2012. 10.1016/j.ejrad.2011.09.003.<pub-id pub-id-type="pmid">22386916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Nomori</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Kawanaka</surname><given-names>K</given-names></name><name><surname>Shiraishi</surname><given-names>S</given-names></name><name><surname>Katahira</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography</article-title><source>J Thorac Oncol</source><year>2008</year><pub-id pub-id-type="doi">10.1097/JTO.0b013e318168d9ed</pub-id><pub-id pub-id-type="pmid">18758311</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol. 2008. 10.1097/JTO.0b013e318168d9ed.<pub-id pub-id-type="pmid">18758311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Tyng</surname><given-names>CJ</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>MD</given-names></name><name><surname>Bitencourt</surname><given-names>AGV</given-names></name><name><surname>dos Santos</surname><given-names>LCM</given-names></name><name><surname>Barbosa</surname><given-names>PNVP</given-names></name><name><surname>Zurstrassen</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Correlation of the ADC values assessed by diffusion-weighted MRI and 18F&#x02013;FDG PET/CT SUV in patients with lung cancer</article-title><source>Appl Cancer Res</source><year>2018</year><pub-id pub-id-type="doi">10.1186/s41241-018-0060-1</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Tyng CJ, Guimar&#x000e3;es MD, Bitencourt AGV, dos Santos LCM, Barbosa PNVP, Zurstrassen CE, et al. Correlation of the ADC values assessed by diffusion-weighted MRI and 18F&#x02013;FDG PET/CT SUV in patients with lung cancer. Appl Cancer Res. 2018. 10.1186/s41241-018-0060-1.</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>SD</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Mund</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation</article-title><source>Hum Mol Genet</source><year>2019</year><pub-id pub-id-type="doi">10.1093/hmg/ddz095</pub-id><pub-id pub-id-type="pmid">31091306</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Rhodes SD, He Y, Smith A, Jiang L, Lu Q, Mund J, et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet. 2019. 10.1093/hmg/ddz095.<pub-id pub-id-type="pmid">31091306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Brohl</surname><given-names>AS</given-names></name><name><surname>Kahen</surname><given-names>E</given-names></name><name><surname>Yoder</surname><given-names>SJ</given-names></name><name><surname>Teer</surname><given-names>JK</given-names></name><name><surname>Reed</surname><given-names>DR</given-names></name></person-group><article-title>The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation</article-title><source>Sci Rep</source><year>2017</year><pub-id pub-id-type="doi">10.1038/s41598-017-15183-1</pub-id><pub-id pub-id-type="pmid">29118384</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017. 10.1038/s41598-017-15183-1.<pub-id pub-id-type="pmid">29118384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Cree</surname><given-names>IA</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><etal/></person-group><article-title>The 2021 WHO classification of tumors of the Central Nervous System: a summary</article-title><source>Neuro Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.1093/neuonc/noab106</pub-id><pub-id pub-id-type="pmid">34596684</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021. 10.1093/neuonc/noab106.<pub-id pub-id-type="pmid">34596684</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>